Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
Publication
, Conference
Penson, RT; Arend, RC; Secord, AA; Herraez, AC; Herzog, TJ; Ledermann, JA; Moore, KN; Shapira-Frommer, R; Tewari, KS; Minei, TR; Harats, D ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Penson, R. T., Arend, R. C., Secord, A. A., Herraez, A. C., Herzog, T. J., Ledermann, J. A., … Monk, B. J. (2022). Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Penson, Richard T., Rebecca Christian Arend, Angeles Alvarez Secord, Antonio Casado Herraez, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, et al. “Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Penson RT, Arend RC, Secord AA, Herraez AC, Herzog TJ, Ledermann JA, et al. Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Penson, Richard T., et al. “Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Penson RT, Arend RC, Secord AA, Herraez AC, Herzog TJ, Ledermann JA, Moore KN, Shapira-Frommer R, Tewari KS, Minei TR, Harats D, Shmueli SF, Monk BJ. Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences